Alkermes Plc (ALKS):企業の財務・戦略的SWOT分析

◆英語タイトル:Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15778
◆発行会社(調査会社):GlobalData
◆発行日:2019年4月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アイルランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Alkermes Plc (ALKS) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Alkermes Plc (Alkermes) is a biopharmaceutical company that focuses on the research, development and commercialization of drugs for the treatment of central nervous system (CNS) diseases. The company’s proprietary products include Aristada, an extended-release intramuscular injectable suspension for the treatment of schizophrenia; and Vivitrol, a once-monthly, non-addictive, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence. It also grants license under its proprietary technologies to enable third parties to develop, commercialize and manufacture products. Alkermes sells its products primarily to wholesalers, specialty distributors and specialty pharmacies. The company also has a clinical pipeline of products that address CNS disorders such as multiple sclerosis, schizophrenia, depression and addiction. Alkermes is headquartered in Dublin, Ireland.

Alkermes Plc Key Recent Developments

Mar 22,2019 Alkermes Statement on National Academies of Sciences, Engineering, and Medicine Report on Medications for Opioid Use Disorder
Feb 14,2019 Alkermes Reports Financial Results for the Year Ended Dec. 31, 2018 and Provides Financial Expectations for 2019
Jan 16,2019 Alkermes announces recipients of 1st annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) Program

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Alkermes Plc – Key Facts
Alkermes Plc – Key Employees
Alkermes Plc – Key Employee Biographies
Alkermes Plc – Major Products and Services
Alkermes Plc – History
Alkermes Plc – Company Statement
Alkermes Plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Alkermes Plc – Business Description
Geographical Segment: Ireland
Performance
Geographical Segment: Rest of world
Performance
Geographical Segment: US
Performance
R&D Overview
Alkermes Plc – Corporate Strategy
Alkermes Plc – SWOT Analysis
SWOT Analysis – Overview
Alkermes Plc – Strengths
Alkermes Plc – Weaknesses
Alkermes Plc – Opportunities
Alkermes Plc – Threats
Alkermes Plc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Alkermes Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 22, 2019: Alkermes Statement on National Academies of Sciences, Engineering, and Medicine Report on Medications for Opioid Use Disorder
Feb 14, 2019: Alkermes Reports Financial Results for the Year Ended Dec. 31, 2018 and Provides Financial Expectations for 2019
Jan 16, 2019: Alkermes announces recipients of 1st annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) Program
Nov 30, 2018: Statement by Richard Pops, Chairman and CEO of Alkermes on the annual CDC report on Drug Overdose deaths and suicide mortality in the United States
Nov 29, 2018: Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia
Oct 29, 2018: Alkermes Announces Publication of Phase 3 Data for ALKS 5461 for Adjunctive Treatment of Major Depressive Disorder in Molecular Psychiatry
Oct 26, 2018: Alkermes announces recipients of 3rd Annual ALKERMES INSPIRATION GRANTS
Oct 26, 2018: Alkermes announces recipients of 3rd Annual ALKERMES INSPIRATION GRANTS
Oct 23, 2018: Alkermes announces third quarter 2018 financial results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Alkermes Plc, Key Facts
Alkermes Plc, Key Employees
Alkermes Plc, Key Employee Biographies
Alkermes Plc, Major Products and Services
Alkermes Plc, History
Alkermes Plc, Other Locations
Alkermes Plc, Subsidiaries
Alkermes Plc, Key Competitors
Alkermes Plc, Ratios based on current share price
Alkermes Plc, Annual Ratios
Alkermes Plc, Annual Ratios (Cont...1)
Alkermes Plc, Annual Ratios (Cont...2)
Alkermes Plc, Interim Ratios
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Alkermes Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Alkermes Plc, Performance Chart (2014 - 2018)
Alkermes Plc, Ratio Charts
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Alkermes Plc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Alkermes Plc (ALKS):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Osaka Gas Co., Ltd.:戦略・SWOT・企業財務分析
    Osaka Gas Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Osaka Gas Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • International AIDS Vaccine Initiative:製薬・医療:M&Aディール及び事業提携情報
    Summary International AIDS Vaccine Initiative (IAVI) is a not-for-profit organization that develops preventive HIV vaccine candidates. The organization offers vaccine development through basic research, discovery, preclinical evaluation and manufacturing, and regulatory review, among others. Its pro …
  • New Hoong Fatt Holdings Bhdの企業概要及び財務/SWOT分析
    New Hoong Fatt Holdings Bhd Fundamental Company Report provides a complete overview of the company’s affairs. The report includes financial and SWOT information, industry analysis, opinions, estimates, New Hoong Fatt Holdings Bhd annual and quarterly forecasts made by stock market experts. The repor …
  • Hamilton Thorne Ltd (HTL):医療機器:M&Aディール及び事業提携情報
    Summary Hamilton Thorne Ltd (Hamilton Thorne) is a medical equipment company that offers precision laser devices and advanced image analysis systems. The company's products include clinical lasers, animal and research sperm analysis products, research lasers, clinical sperm analysis products, sperm …
  • Impala Platinum Holdings Ltd:企業の戦略・SWOT・財務情報
    Impala Platinum Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Impala Platinum Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Veolia Environnement SA (VIE):企業のM&A・提携動向(発電分野)
    Summary Veolia Environnement SA (Veolia) is an environmental management services company that designs and offers water, waste and energy management solutions. Its service offerings include wastewater and sanitation services, drinking water treatment and distribution, and waste management and energy …
  • Daewoo Engineering & Construction Co., Ltd. (047040):企業のM&A・提携動向(エネルギー分野)
    Summary Daewoo Engineering & Construction Co. Ltd. (Daewoo E&C) is an engineering and construction company. It provides engineering, architecture and construction services to diverse end markets. The company handles a wide variety of construction projects including roads, bridges, railroads, residen …
  • Discus Dental, Inc:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Discus Dental, Inc Mergers and …
  • Air Liquide SA (AI):企業のM&A・提携動向(医療分野)
    Summary Air Liquide SA (Air Liquide) is a provider of gases, technologies and services for industry and health. The company produces core air gases such as oxygen, nitrogen, and hydrogen along with argon and other rare gases. It supplies gases to customers in multiple industries, including steel, fo …
  • Bosch Sensortec GmbH:企業の戦略的SWOT分析
    Bosch Sensortec GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Northern Trust Wealth Management (NTRS):企業概要・SWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "Northern Trust Wealth Management" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. Timetric s …
  • Sumitomo Mitsui Financial Group, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Sumitomo Mitsui Financial Group …
  • Yahoo!7 Pty Limited:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Yahoo!7 Pty Limited Mergers and …
  • Raser Technologies, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Raser Technologies, Inc. Merger …
  • Hagoromo Foods Corporation:企業の戦略・SWOT・財務分析
    SummaryHagoromo Foods Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. …
  • Chesnara plc:企業の戦略・SWOT・財務情報
    Chesnara plc - Strategy, SWOT and Corporate Finance Report Summary Chesnara plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Shanghai International Port (Group) Co., Ltd.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Shanghai International Port (Gr …
  • MRI Interventions Inc (MRIC):企業の製品パイプライン分析2018
    Summary MRI Interventions Inc (MRI Interventions) is a medical equipment company that develops and commercializes platforms for performing invasive surgical procedures. The company’s products include systems used for performing invasive surgeries on brain and heart. Its products are used for treatin …
  • Massachusetts Institute of Technology-製薬・医療分野:企業M&A・提携分析
    Summary Massachusetts Institute of Technology (MIT) is a research university that provides contract research and education. The institute offers education in the areas of computer science, biology, aeronautics, mechanical engineering, civil engineering, economics, electrical engineering, literature, …
  • Escalier Biosciences BV:製薬・医療:M&Aディール及び事業提携情報
    Summary Escalier Biosciences BV (Escalier Biosciences) is a biopharmaceutical company, which develops small molecule medicines for the treatment of autoimmune disorders. Its pipeline products include topical and oral RAR-related orphan receptor gamma inverse agonists. Inhibition of RAR-related orpha …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆